In triple-negative breast cancer, a novel peptide–drug conjugate exploits enhanced albumin metabolism in PTEN-deficient cells to deliver chemotherapeutic payloads, showing promise against metastatic disease [110]. This evidence concerns the gene ALB and metastatic neoplasm.